Karyopharm Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Karyopharm Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
NEWTON, Mass., Sept. 3, 2024 /PRNewswire/ -- Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced that the Company granted an aggregate of 22,050 restricted stock units (RSUs) to five newly-hired employees. These RSU awards were granted as of August 31, 2024 (the "Grant Date") pursuant to the Company's 2022 Inducement Stock Incentive Plan, as amended, as inducements material to the new employees entering into employment with Karyopharm in accordance with Nasdaq Listing Rule 5635(c)(4).
2024年9月3日，马萨诸塞州纽顿/PRNewswire/ -- karyopharm therapeutics inc.(纳斯达克: KPTI) ，一个开创性的商业阶段的药品公司，致力于创新癌症治疗方案, 今天宣布，公司已经向五名新入职员工授予了合计22,050股受限制的股票单位(RSUs) 。这些RSU奖励于2024年8月31日(“授予日期”)根据公司的2022年诱因股票激励计划进行授予，根据纳斯达克交易所3435(c)(4)条款，作为吸引新员工与karyopharm签订就业合同的物质激励。
Each RSU award will vest over three years, with 33 1/3% of the shares underlying the RSU award vesting on each of the three consecutive anniversaries of the Grant Date. The vesting of each RSU award is subject to the employee's continued service as an employee of, or other service provider to, Karyopharm through the applicable vesting dates. In addition, each RSU award will be immediately exercisable in full if, on or prior to the first anniversary of the consummation of a "change in control event," the employee's employment is terminated for "good reason" by the employee or terminated without "cause" by Karyopharm (as such terms are defined in the applicable RSU agreement).
每个RSU奖励将在三年内分期归属，其中每个RSU奖励股份的33 1/3％将在授予日之后的三个连续周年纪念日上获得。每个RSU奖励的归属取决于员工在适用归属日期之前作为Karyopharm的雇员或其他服务提供商的继续服务。此外，如果在“控制权变更事件”完成的第一周年纪念日之前，员工因“良好的理由”被员工解雇或被Karyopharm无“原因”解雇，则每个RSU奖励将立即完全行权（如适用的RSU协议中所定义）。
About Karyopharm Therapeutics
关于Karyopharm Therapeutics
Karyopharm Therapeutics Inc. (Nasdaq: KPTI) is a commercial-stage pharmaceutical company whose dedication to pioneering novel cancer therapies is fueled by a belief in the extraordinary strength and courage of patients with cancer. Since its founding, Karyopharm has been an industry leader in oral compounds that address nuclear export dysregulation, a fundamental mechanism of oncogenesis. Karyopharm's lead compound and firstinclass, oral exportin 1 (XPO1) inhibitor, XPOVIO (selinexor), is approved in the U.S. and marketed by the Company in three oncology indications. It has also received regulatory approvals in various indications in a growing number of exU.S. territories and countries, including Europe and the United Kingdom (as NEXPOVIO) and China. Karyopharm has a focused pipeline targeting indications in multiple high unmet need cancers, including in multiple myeloma, endometrial cancer, myelofibrosis, and diffuse large B-cell lymphoma (DLBCL). For more information about our people, science and pipeline, please visit , and follow us on LinkedIn and on X at @Karyopharm.
Karyopharm Therapeutics Inc. （纳斯达克：KPTI）是一家商业化阶段的药品公司，致力于开发新型肿瘤治疗方法，相信癌症患者的强大力量和勇气。自成立以来，Karyopharm公司一直是口服化合物领域的领导者，这些化合物解决了核蛋白运输调节的基本机制。Karyopharm的主导化合物和首个口服exportin 1（XPO1）抑制剂XPOVIO（selinexor）已在美国获得批准，并由该公司用于三种肿瘤治疗。它还在不断增加的海外地区和国家（包括欧洲和英国[NEXPOVIO]和中国）获得多种适应症的监管批准。Karyopharm的专注产品线针对多种高度未满足的癌症适应症，包括多发性骨髓瘤，子宫内膜癌，骨髓纤维化和弥漫性大B细胞淋巴瘤（DLBCL）。有关我们的人员，科学和产品线的更多信息，请访问，并在领英和X上关注我们@Karyopharm。
XPOVIO and NEXPOVIO are registered trademarks of Karyopharm Therapeutics Inc.
XPOVIO和NEXPOVIO是Karyopharm Therapeutics Inc.的注册商标。
SOURCE Karyopharm Therapeutics Inc.
SOURCE Karyopharm Therapeutics Inc.